Anders Pedersen

Anders Pedersen

Chairman chez AELIS FARMA

Fortune : 3 M $ au 31/03/2024

73 ans
Health Technology
Consumer Services
Health Services

Profil

Anders Gersel Pedersen is currently the Chief Executive Officer at Gerselconsult ApS.
He is also the Deputy Chairman at Bavarian Nordic A and Bavarian Nordic GmbH.
Additionally, he serves as the Chairman of Fonden Lundbeck International Neuroscience Foundation and Aelis Farma SA. Dr. Pedersen is a Non-Independent Director at Genmab A and an Independent Director at Hansa Biopharma AB.
He is also a Director at Lundbeck Cognitive Therapeutics A, Bond 2 Development 2 Gp Ltd., and Bond Avillion 2 Development LP.
Furthermore, he is a Member of the American Society of Clinical Oncology, Inc., the European Society for Medical Oncology, the International Association for the Study of Lung Cancer, the Danish Society of Medical Oncology, and the Danish Society of Internal Medicine.
Dr. Pedersen joined Avillion LLP in 2019 as a Member-Supervisory Board.
Dr. Pedersen previously worked as an Executive Director at Eli Lilly & Co. He was also a Director at Topotarget A and Chr.
Hansen A.
Additionally, he served as a Director at TopoTarget UK Ltd.
Dr. Pedersen worked at H.
Lundbeck A from 2000 to 2018, where he held the position of Executive Vice President-Research & Development.
He was an Independent Director at ALK-Abello A from 2005 to 2018.
Dr. Pedersen completed his undergraduate studies at Copenhagen Business School and obtained a doctorate degree from the University of Copenhagen.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
14/02/2024 9 292 ( 0,01% ) 3 M $ 31/03/2024
31/12/2022 16 959 ( 0,02% ) 380 482 $ 31/03/2024
31/12/2022 2 500 ( 0,00% ) 6 804 $ 31/03/2024

Postes actifs de Anders Pedersen

SociétésPosteDébut
BAVARIAN NORDIC A/S Director/Board Member 27/04/2010
GENMAB A/S Director/Board Member 01/11/2003
HANSA BIOPHARMA AB Director/Board Member 29/05/2018
AELIS FARMA Chairman -
Bond Avillion 2 Development LP Director/Board Member -
Bond 2 Development 2 Gp Ltd. Director/Board Member -
Director/Board Member 05/09/2019
Director/Board Member 01/01/2014
Lundbeck Cognitive Therapeutics A/S Director/Board Member -
░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░ -
Tous les postes actifs de Anders Pedersen

Anciens postes connus de Anders Pedersen

SociétésPosteFin
░░ ░░░░░░░░ ░░░ ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░░░░░░ ░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░░░ ░░░ ░░░░░░░░░░░░░░ ░░░░░░ -
░░░░ ░░░░░░ ░░░ ░░░░░░░░░░░░░░ ░░░░░░ -
░░░ ░░░░░ ░░░ ░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ -
Voir l'expérience en détail de Anders Pedersen

Formation de Anders Pedersen

Copenhagen Business School Undergraduate Degree
University of Copenhagen Doctorate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Anders Pedersen

Relations

100 +

Relations au 1er degré

24

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées7
ELI LILLY AND COMPANY

Health Technology

H. LUNDBECK A/S

Health Technology

GENMAB A/S

Health Technology

BAVARIAN NORDIC A/S

Health Technology

ALK-ABELLÓ A/S

Health Technology

HANSA BIOPHARMA AB

Health Technology

AELIS FARMA

Health Technology

Entreprise privées15

Health Technology

Health Technology

Retail Trade

Health Services

Health Services

International Association for the Study of Lung Cancer

Danish Society of Medical Oncology

Danish Society of Internal Medicine

Fonden Lundbeck International Neuroscience Foundation

Miscellaneous

Health Technology

Bond 2 Development 2 Gp Ltd.

Bond Avillion 2 Development LP

Gerselconsult ApS

Health Technology

Lundbeck Cognitive Therapeutics A/S

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Anders Pedersen